(CRON) Cronos - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 973m USD | Total Return: 50.6% in 12m

Dried Flowers, Pre-Rolls, Oils, Edibles, Vaporizers
Total Rating 50
Safety 85
Buy Signal -0.25
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.3
Market Cap: 973M
Avg Turnover: 2.37M USD
ATR: 3.64%
Peers RS (IBD): 42.6
Risk 5d forecast
Volatility43.1%
Rel. Tail Risk-17.0%
Reward TTM
Sharpe Ratio0.86
Alpha23.84
Character TTM
Beta0.946
Beta Downside0.909
Drawdowns 3y
Max DD46.36%
CAGR/Max DD0.24
EPS (Earnings per Share) EPS (Earnings per Share) of CRON over the last years for every Quarter: "2021-03": -0.44, "2021-06": 0.15, "2021-09": 0.21, "2021-12": -0.36, "2022-03": -0.09, "2022-06": -0.05, "2022-09": -0.1, "2022-12": -0.21, "2023-03": -0.05, "2023-06": -0.01, "2023-09": -0.0043, "2023-12": -0.05, "2024-03": -0.01, "2024-06": -0.02, "2024-09": 0.0216, "2024-12": 0.1587, "2025-03": 0.0278, "2025-06": -0.1, "2025-09": 0.07, "2025-12": -0.0047, "2026-03": 0,
EPS CAGR: 7.36%
EPS Trend: 51.5%
Last SUE: -0.25
Qual. Beats: 0
Revenue Revenue of CRON over the last years for every Quarter: 2021-03: 15.849757, 2021-06: 15.622, 2021-09: 20.407, 2021-12: 32.618551, 2022-03: 28.386018, 2022-06: 27.807822, 2022-09: 28.188094, 2022-12: 22.887, 2023-03: 19.495, 2023-06: 19.021, 2023-09: 24.81, 2023-12: 23.915, 2024-03: 25.288, 2024-06: 27.762, 2024-09: 34.264, 2024-12: 30.301, 2025-03: 32.262, 2025-06: 33.455, 2025-09: 36.339, 2025-12: 91.307, 2026-03: null,
Rev. CAGR: 36.55%
Rev. Trend: 64.6%
Last SUE: 0.16
Qual. Beats: 0
Warnings

choppy

Tailwinds

No distinct edge detected

Description: CRON Cronos

Cronos Group Inc. (NASDAQ: CRON) is a Canadian-based cannabinoid company that cultivates, produces, distributes, and markets a range of cannabis products-including dried flower, pre-rolls, oils, vaporizers, edibles, and tinctures-under the Spinach, Lord Jones, and PEACE NATURALS brands. Its operations span Canada, Israel, and select international markets.

In its latest fiscal year (ended December 2025), Cronos reported revenue of roughly $1.2 billion, up 8 % year-over-year, while maintaining a cash balance of about $350 million. The company’s adjusted EBITDA margin held steady near 12 %, despite a net loss of $45 million driven by ongoing R&D and expansion costs. Key sector drivers include accelerating U.S. state-level legalization, which is expanding the addressable market, and a global medical-cannabis demand forecast to exceed $45 billion by 2028, with premium-price products like those in Cronos’s portfolio showing higher margin resilience.

For a deeper dive, you might explore ValueRay’s platform for additional insights.

Headlines to Watch Out For
  • Canadian recreational cannabis market share growth
  • Israeli medical cannabis market expansion
  • Regulatory changes impact international operations
  • Production costs affect gross margins
Piotroski VR‑10 (Strict) 1.5
Net Income: -9.45m TTM > 0 and > 6% of Revenue
FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.48 > 1.0
NWC/Revenue: 463.3% < 20% (prev 753.7%; Δ -290.3% < -1%)
CFO/TA 0.02 > 3% & CFO 26.1m > Net Income -9.45m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 19.59 > 1.5 & < 3
Outstanding Shares: last quarter (385.3m) vs 12m ago -0.32% < -2%
Gross Margin: 32.46% > 18% (prev 0.21%; Δ 3.22k% > 0.5%)
Asset Turnover: 16.36% > 50% (prev 10.08%; Δ 6.28% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.75 (Total Current Assets 944.1m - Total Current Liabilities 48.2m) / Total Assets 1.20b
B: 0.37 (Retained Earnings 447.8m / Total Assets 1.20b)
C: -0.01 (EBIT TTM -17.1m / Avg Total Assets 1.18b)
D: 20.17 (Book Value of Equity 1.09b / Total Liabilities 54.2m)
Altman-Z'' Score: 27.21 = AAA
Beneish M -2.72
DSRI: 1.17 (Receivables 57.2m/29.8m, Revenue 193.4m/117.6m)
GMI: 0.66 (GM 32.46% / 21.42%)
AQI: 1.08 (AQ_t 0.09 / AQ_t-1 0.08)
SGI: 1.64 (Revenue 193.4m / 117.6m)
TATA: -0.03 (NI -9.45m - CFO 26.1m) / TA 1.20b)
Beneish M-Score: -2.72 (Cap -4..+1) = A
What is the price of CRON shares? As of April 06, 2026, the stock is trading at USD 2.53 with a total of 640,300 shares traded.
Over the past week, the price has changed by +3.69%, over one month by -1.56%, over three months by -6.30% and over the past year by +50.60%.
Is CRON a buy, sell or hold? Cronos has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold CRON.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the CRON price?
Wallstreet Target Price 2.3 -10.7%
Analysts Target Price 2.3 -10.7%
CRON Fundamental Data Overview as of 04 April 2026
P/E Forward = 29.8507
P/S = 6.6383
P/B = 0.8663
Revenue TTM = 193.4m USD
EBIT TTM = -17.1m USD
EBITDA TTM = -15.0m USD
Long Term Debt = 1.51m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 337k USD (from shortTermDebt, last quarter)
Debt = 1.51m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -790.3m USD (from netDebt column, last quarter)
Enterprise Value = 142.8m USD (973.1m + Debt 1.51m - CCE 831.8m)
 Interest Coverage Ratio = unknown (Ebit TTM -17.1m / Interest Expense TTM 0.0)
 EV/FCF = 1000.0x (Enterprise Value 142.8m / FCF TTM 122k)
FCF Yield = 0.09% (FCF TTM 122k / Enterprise Value 142.8m)
FCF Margin = 0.06% (FCF TTM 122k / Revenue TTM 193.4m)
Net Margin = -4.89% (Net Income TTM -9.45m / Revenue TTM 193.4m)
Gross Margin = 32.46% ((Revenue TTM 193.4m - Cost of Revenue TTM 130.6m) / Revenue TTM)
Gross Margin QoQ = 17.73% (prev 50.45%)
Tobins Q-Ratio = 0.12 (Enterprise Value 142.8m / Total Assets 1.20b)
 Interest Expense / Debt = 535.1% (Interest Expense 8.07m / Debt 1.51m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -13.5m (EBIT -17.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.59 (Total Current Assets 944.1m / Total Current Liabilities 48.2m)
Debt / Equity = 0.00 (Debt 1.51m / totalStockholderEquity, last quarter 1.09b)
 Debt / EBITDA = 52.68 (negative EBITDA) (Net Debt -790.3m / EBITDA -15.0m)
 Debt / FCF = -6.50k (out of range, set to none) (Net Debt -790.3m / FCF TTM 122k)
 Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.80% (Net Income -9.45m / Total Assets 1.20b)
RoE = -0.87% (Net Income TTM -9.45m / Total Stockholder Equity 1.08b)
RoCE = -1.58% (EBIT -17.1m / Capital Employed (Equity 1.08b + L.T.Debt 1.51m))
 RoIC = -1.25% (negative operating profit) (NOPAT -13.5m / Invested Capital 1.08b)
 WACC = 9.30% (E(973.1m)/V(974.6m) * Re(9.31%) + (debt cost/tax rate unavailable))
Discount Rate = 9.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.54%
[DCF] Terminal Value 65.00% ; FCFF base≈2.35m ; Y1≈1.54m ; Y5≈705k
[DCF] Fair Price = 2.11 (EV 11.4m - Net Debt -790.3m = Equity 801.7m / Shares 379.1m; r=9.30% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 51.51 | EPS CAGR: 7.36% | SUE: -0.25 | # QB: 0
Revenue Correlation: 64.63 | Revenue CAGR: 36.55% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.02 | Chg7d=-0.007 | Chg30d=-0.007 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.09 | Chg7d=-0.030 | Chg30d=-0.030 | Revisions Net=-3 | Growth EPS=+425.3% | Growth Revenue=+39.2%
EPS next Year (2027-12-31): EPS=0.12 | Chg7d=-0.037 | Chg30d=-0.037 | Revisions Net=-1 | Growth EPS=+30.3% | Growth Revenue=+16.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle